Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Cyrinne Achour et al.
Summary: This study identifies a specific alternative splicing (AS) signature associated with breast tumorigenesis and reveals the role of METTL3 in modulating breast cancer-associated AS programs. It also demonstrates that m(6)A deposition in splice site boundaries and in splicing and transcription factor transcripts can directly regulate AS switches of specific breast cancer-associated transcripts. Furthermore, the study suggests that five validated AS events in vitro are associated with a poor overall survival rate for patients with breast cancer, indicating their potential as novel prognostic biomarkers.
Review
Biochemistry & Molecular Biology
Wangyang Meng et al.
Summary: Aberrant translation in cancer is regulated by RNA binding proteins (RBPs) in the translation machinery. N6-methyladenosine (m(6)A) modifications mediated by METTL3 are the most abundant internal modifications in mRNAs. METTL3 is aberrantly expressed in different tumors and affects mRNA translation of oncogenes or tumor suppressor genes. This review discusses the critical roles of METTL3 in translation regulation and the collaboration between METTL3, m(6)A reader proteins, and RBPs in promoting aberrant translation in tumorigenesis.
Article
Oncology
Alberto Bueno-Costa et al.
Article
Multidisciplinary Sciences
Eliza Yankova et al.
Summary: The study identified a highly potent and selective catalytic inhibitor of METTL3, STM2457, which shows potential therapeutic value in treating AML. Treatment with this inhibitor leads to reduced AML growth, increased differentiation and apoptosis, and decreased m(6)A levels on leukemogenic mRNAs. In vivo pharmacological inhibition of METTL3 results in impaired engraftment and prolonged survival in mouse models of AML.
Review
Hematology
Sisi Chen et al.
Summary: Mutations in genes encoding RNA splicing factors are now known to play a key role in various blood disorders, leading to research on biological pathways disrupted by altered splicing and the development of new therapeutic approaches.
Review
Oncology
Margalida Rossello-Tortella et al.
BLOOD CANCER DISCOVERY
(2020)
Article
Biochemistry & Molecular Biology
Laia Pique et al.
Article
Medicine, Research & Experimental
Elisa ten Hacken et al.
Article
Oncology
Zejuan Li et al.
